Cutera, Inc. (NASDAQ:CUTR) had its target price hoisted by equities researchers at Roth Capital from $32.00 to $39.00 in a research report issued on Tuesday. The brokerage presently has a “buy” rating on the medical device company’s stock. Roth Capital’s price target would suggest a potential upside of 46.34% from the stock’s current price.

CUTR has been the topic of a number of other research reports. Sidoti started coverage on Cutera in a report on Tuesday, April 11th. They set a “buy” rating and a $27.00 target price on the stock. Zacks Investment Research upgraded Cutera from a “sell” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Tuesday, June 20th. BidaskClub cut Cutera from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. TheStreet cut Cutera from a “b-” rating to a “c” rating in a report on Monday, May 1st. Finally, Maxim Group reiterated a “buy” rating and set a $33.00 price objective (up previously from $27.00) on shares of Cutera in a report on Thursday, July 13th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $33.25.

Shares of Cutera (CUTR) opened at 26.65 on Tuesday. Cutera has a 1-year low of $10.54 and a 1-year high of $29.25. The firm’s 50-day moving average is $25.87 and its 200-day moving average is $21.85. The stock has a market capitalization of $369.32 million, a price-to-earnings ratio of 102.11 and a beta of 0.60.

COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/08/cutera-inc-cutr-price-target-increased-to-39-00-by-analysts-at-roth-capital.html.

In other Cutera news, CFO Ronald J. Santilli sold 3,857 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $22.95, for a total value of $88,518.15. Following the sale, the chief financial officer now owns 88,321 shares in the company, valued at approximately $2,026,966.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Larry Laber sold 6,482 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $22.89, for a total value of $148,372.98. Following the completion of the sale, the executive vice president now owns 80,642 shares in the company, valued at approximately $1,845,895.38. The disclosure for this sale can be found here. Insiders have sold a total of 64,563 shares of company stock worth $1,485,360 in the last quarter. 3.30% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. American International Group Inc. boosted its stake in Cutera by 7.0% in the first quarter. American International Group Inc. now owns 7,221 shares of the medical device company’s stock valued at $149,000 after buying an additional 475 shares during the last quarter. Bank of America Corp DE boosted its stake in Cutera by 0.4% in the first quarter. Bank of America Corp DE now owns 139,087 shares of the medical device company’s stock valued at $2,879,000 after buying an additional 500 shares during the last quarter. Federated Investors Inc. PA boosted its stake in Cutera by 2.5% in the second quarter. Federated Investors Inc. PA now owns 58,415 shares of the medical device company’s stock valued at $1,513,000 after buying an additional 1,427 shares during the last quarter. Bessemer Group Inc. boosted its stake in Cutera by 7.7% in the second quarter. Bessemer Group Inc. now owns 25,200 shares of the medical device company’s stock valued at $653,000 after buying an additional 1,800 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in Cutera by 7.3% in the first quarter. Teachers Advisors LLC now owns 41,614 shares of the medical device company’s stock valued at $861,000 after buying an additional 2,820 shares during the last quarter. Hedge funds and other institutional investors own 82.87% of the company’s stock.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.